Gram-negative pathogens producing metallo-?-lactamases, MBLs, seriously threaten the public health. MBLs are the most worrisome carbapenemases, inactivating the ?last resort? carbapenems and most ?-lactams, and resist all commercially available ?-lactamase inhibitors (BLIs). The main challenges in MBL inhibitor design are understanding the reaction mechanism as it relates to the structural diversity of the 3 distinct subclasses (B1, B2, and B3). In the previous 5-year funding cycle, we achieved important milestones: i) identified the active form of clinically relevant MBLs in the bacterial periplasm; ii) characterized NDM-1 as a membrane-bound protein, establishing how this localization endows NDM-1 with unique stability; iii) demonstrated that MBLs of all 3 subclasses utilize a common mechanism for carbapenem hydrolysis suggesting novel approaches for inhibitor development; iv) designed a series of novel compounds, bisthiazolidines (BTZs), as substrate mimics, comprising a non- ?-lactam ?penicillin core? decorated with metal binding groups; and v) showed that BTZs are non-toxic, effective cross-class MBL inhibitors and identified the structural bases of their inhibitory action. Responding to the clear urgency to find novel therapies, our team will build on these accomplishments to identify, synthesize, evaluate and develop new cross-class MBL inhibitors. Our unique approach is based upon a mechanistic understanding of MBL catalysis which will be utilized to inspire potent inhibitors. To this end, we will synthesize new compounds as mimics of mechanistic intermediates or product mimics [Thiazolidines (TZs), ?4- Thiazolidines (?4-TZs), and ?4-Oxazolidines (?4-OXZs)] or carbapenem mimics [?4-Bisthiazolidines (?4-BTZs) and Bicyclooctanes (BCOs)]. Our second specific aim will evaluate inhibitors for in vitro activity against MBLs of all subclasses. We will next assay the impact of inhibitors in potentiating ?-lactam efficacy against MBL- producing model strains, assess differences between in vitro assays and effect on bacteria, and validate the selected inhibitors against a panel of clinical strains with different MBL alleles.
Our third aim will combine NMR and X-ray crystallography to study the structure of MBL-inhibitor adducts aimed to provide details for inhibitor improvement. We will also pursue mechanistic studies using micro-focusing spectroscopy and crystallography coupled to XFEL (X-ray free electron lasers) to trap transient ?-lactam-bound species in the enzymes NDM-1, L1, and VIM. This ?high-risk, high impact? innovative approach using new technologies will provide information for inhibitor improvement. Lastly, we will assay off-target activity and in vitro toxicity of the synthesized compounds, perform time-kill assays for meropenem-BLI combinations in clinical strains; and use mouse blood stream and lung infection models to assess the in vivo potency of meropenem/MBL-inhibitor combinations. This knowledge will serve to inform the design of therapeutic leads to combat MBL producing bacteria.

Public Health Relevance

Metallo-?-lactamases, MBLs, represent the largest family of carbapenemases that inactivate our most potent antibiotics (carbapenems) and are resistant to commercially available ?-lactamase inhibitors. To overcome this challenge our continuing renewal seeks to design and study the inhibitory abilities of a series of novel compounds [thiazolidines (TZs), oxazolidines (OXZs) and bicyclooctanes (BCOs)] that build upon our success with bisthiazolidines (BTZs). This proposal also aims to explore the fundamental biochemistry underlying the MBL resistance profile, applying new crystallographic tools to characterize mechanistic intermediates as leads for drug design, and test these compounds in animal models.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI100560-08
Application #
9947853
Study Section
Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section (DDR)
Program Officer
Xu, Zuoyu
Project Start
2012-02-07
Project End
2023-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
8
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Papp-Wallace, Krisztina M; Barnes, Melissa D; Alsop, Jim et al. (2018) Relebactam Is a Potent Inhibitor of the KPC-2 ?-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Antimicrob Agents Chemother 62:
Tsalik, Ephraim L; Bonomo, Robert A; Fowler Jr, Vance G (2018) New Molecular Diagnostic Approaches to Bacterial Infections and Antibacterial Resistance. Annu Rev Med 69:379-394
Cheng, Zishuo; VanPelt, Jamie; Bergstrom, Alexander et al. (2018) A Noncanonical Metal Center Drives the Activity of the Sediminispirochaeta smaragdinae Metallo-?-lactamase SPS-1. Biochemistry 57:5218-5229
VanPelt, Jamie; Shurina, Ben A; Ramelot, Theresa A et al. (2018) 1H, 13C, and 15N backbone resonance assignments for KPC-2, a class A serine-?-lactamase. Biomol NMR Assign :
Papp-Wallace, Krisztina M; Nguyen, Nhu Q; Jacobs, Michael R et al. (2018) Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using ?-Lactamase Inhibitors and ?-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. J Med Chem 61:4067-4086
Ju, Lin-Cheng; Cheng, Zishuo; Fast, Walter et al. (2018) The Continuing Challenge of Metallo-?-Lactamase Inhibition: Mechanism Matters. Trends Pharmacol Sci 39:635-647
Bahr, Guillermo; Vitor-Horen, Luisina; Bethel, Christopher R et al. (2018) Clinical Evolution of New Delhi Metallo-?-Lactamase (NDM) Optimizes Resistance under Zn(II) Deprivation. Antimicrob Agents Chemother 62:
Bergstrom, Alexander; Katko, Andrew; Adkins, Zach et al. (2018) Probing the Interaction of Aspergillomarasmine A with Metallo-?-lactamases NDM-1, VIM-2, and IMP-7. ACS Infect Dis 4:135-145
Barnes, Melissa D; Taracila, Magdalena A; Rutter, Joseph D et al. (2018) Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa. MBio 9:
Hinchliffe, Philip; Tanner, Carol A; Krismanich, Anthony P et al. (2018) Structural and Kinetic Studies of the Potent Inhibition of Metallo-?-lactamases by 6-Phosphonomethylpyridine-2-carboxylates. Biochemistry 57:1880-1892

Showing the most recent 10 out of 147 publications